- Home
- NUS vs IMMP Comparison
NUS vs IMMP Comparison
Compare NUS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- IMMP
- Stock Information
- Founded
- NUS 1984
- IMMP 1987
- Country
- NUS United States
- IMMP Australia
- Employees
- NUS N/A
- IMMP N/A
- Industry
- NUS Other Pharmaceuticals
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- IMMP Health Care
- Exchange
- NUS Nasdaq
- IMMP Nasdaq
- Market Cap
- NUS 379.5M
- IMMP 221.2M
- IPO Year
- NUS 1996
- IMMP N/A
- Fundamental
- Price
- NUS $8.92
- IMMP $1.72
- Analyst Decision
- NUS Hold
- IMMP Buy
- Analyst Count
- NUS 2
- IMMP 1
- Target Price
- NUS $6.88
- IMMP $7.00
- AVG Volume (30 Days)
- NUS 504.2K
- IMMP 98.8K
- Earning Date
- NUS 08-07-2025
- IMMP 02-27-2025
- Dividend Yield
- NUS 2.69%
- IMMP N/A
- EPS Growth
- NUS N/A
- IMMP N/A
- EPS
- NUS N/A
- IMMP N/A
- Revenue
- NUS $1,679,268,000.00
- IMMP $3,019,249.00
- Revenue This Year
- NUS N/A
- IMMP $50.37
- Revenue Next Year
- NUS N/A
- IMMP N/A
- P/E Ratio
- NUS N/A
- IMMP N/A
- Revenue Growth
- NUS N/A
- IMMP 24.11
- 52 Week Low
- NUS $5.32
- IMMP $1.32
- 52 Week High
- NUS $11.64
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- NUS 67.91
- IMMP 52.01
- Support Level
- NUS $7.86
- IMMP $1.53
- Resistance Level
- NUS $8.16
- IMMP $1.71
- Average True Range (ATR)
- NUS 0.34
- IMMP 0.07
- MACD
- NUS 0.08
- IMMP 0.01
- Stochastic Oscillator
- NUS 92.57
- IMMP 80.62
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.